Support The Moscow Times!

Russian Market Boosts Drug Maker Stada's Q3

German generic drug maker Stada posted a 7 percent rise in nine-month adjusted core earnings, as higher sales of drugs in Russia offset a decline in its domestic market.

Adjusted earnings before interest, tax, depreciation and amortization, or EBITDA, rose to 284 million euros ($397 million) in the first nine months of 2013, just shy of market expectations for 287 million euros.

Stada still sees high single-digit percentage growth in full-year adjusted EBITDA and it confirmed its target for 2014 net income of 215 million euros, up from 86.5 million in 2012.

Read more

Independent journalism isn’t dead. You can help keep it alive.

As the only remaining independent, English-language news source reporting from Russia, The Moscow Times plays a critical role in connecting Russia to the world.

Editorial decisions are made entirely by journalists in our newsroom, who adhere to the highest ethical standards. We fearlessly cover issues that are often considered off-limits or taboo in Russia, from domestic violence and LGBT issues to the climate crisis and a secretive nuclear blast that exposed unknowing doctors to radiation.

Please consider making a one-time donation — or better still a recurring donation — to The Moscow Times to help us continue producing vital, high-quality journalism about the world's largest country.